News
Sports
Life
Opinion
Business
Advertise
Obituaries
eNewspaper
Legals
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
NewsOK Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mainz Biomed N.V. - Ordinary Shares
(NQ:
MYNZ
)
0.3350
+0.0150 (+4.69%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mainz Biomed N.V. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023
March 01, 2023
Mainz Biomed to host several events for patients and healthcare professionals in Germany to increase awareness about the importance of early detection of colorectal cancer.
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Appear on ClearThink IR’s Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ET
February 28, 2023
Virtual Fireside Chat via Paltalk Platform
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed’s Milestones Reached In 2022 Can Be Catalysts In 1/H 2023…Here’s Why ($MYNZ)
February 28, 2023
Via
AB Newswire
Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
February 21, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK
February 15, 2023
Continued roll-out in Europe with onboarding of new lab partners
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
January 18, 2023
Patient Access Initiative Addresses €1 Billion Annual Market in Germany
From
Mainz BioMed NV
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2023
February 10, 2023
Via
Benzinga
Mainz Biomed Provides Year-End 2022 Corporate Review
January 03, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
December 20, 2022
From
Mainz BioMed NV
Via
GlobeNewswire
Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
December 06, 2022
Gainers Summit Therapeutics Inc. (NASDAQ: SMMT) shares surged 82.2% to $1.4299 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
December 06, 2022
Via
Benzinga
Why MEI Pharma Shares Are Trading Lower By Around 35%; Here Are 20 Stocks Moving Premarket
December 06, 2022
Gainers Starry Group Holdings, Inc. (NYSE: STRY) shares rose 43.5% to $0.2011 in pre-market trading after dipping more than 20% on Monday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
December 06, 2022
Good morning, trader! We're starting off the day with a breakdown of the biggest pre-market stock movers for Tuesday morning!
Via
InvestorPlace
Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study
December 06, 2022
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies
November 29, 2022
Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience as an in vitro diagnostics (IVD) industry leader
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
November 22, 2022
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert
November 15, 2022
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Provides Third Quarter 2022 Update
November 02, 2022
From
Mainz BioMed NV
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022
October 25, 2022
Upgrades
Via
Benzinga
Mainz Biomed’s Colorectal And Pancreatic Cancer Screening Diagnostics Are More Than Life Savers, They Are Significant Value Drivers ($MYNZ)
October 17, 2022
Via
AB Newswire
Mainz Biomed Best-In-Class Colorectal Cancer Screening Diagnostics Expand International Presence, Targets Billion Dollar Market Opportunities ($MYNZ)
October 11, 2022
Via
AB Newswire
12 Health Care Stocks Moving In Friday's After-Market Session
October 07, 2022
Gainers
Via
Benzinga
Mainz Biomed Best-In-Class Cancer Screening Diagnostics Tap Into Billion Dollar Market Opportunities ($MYNZ)
October 04, 2022
Via
AB Newswire
Mainz Biomed Stock Higher; Market Expansion Of Its Best-In-Class Cancer Diagnostics Power The Move ($MYNZ)
September 29, 2022
Via
AB Newswire
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
September 29, 2022
Via
AB Newswire
Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts
September 28, 2022
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed (NASDAQ:MYNZ) could storm Wall Street with its molecular genetic diagnostic solutions for life-threatening conditions
September 27, 2022
Via
AB Newswire
Exposures
Product Safety
Mainz Biomed Targets Multi-Billion Dollar Sales Opportunities With Best-In-Class Cancer Screening Diagnostics ($MYNZ)
September 26, 2022
Via
AB Newswire
Biotech Stocks could be recession proof as bond market plunges (MYNZ, RVNC, AXSM, ABBV)
September 26, 2022
Via
AB Newswire
Topics
Bonds
Economy
Stocks
Exposures
Debt Markets
Economy
Interest Rates
This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday
August 17, 2022
Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.